536 related articles for article (PubMed ID: 11668591)
1. Blockade of NMDA receptors by MK-801 reverses the changes in striatal glutamate immunolabeling in 6-OHDA-lesioned rats.
Robinson S; Krentz L; Moore C; Meshul CK
Synapse; 2001 Oct; 42(1):54-61. PubMed ID: 11668591
[TBL] [Abstract][Full Text] [Related]
2. Haloperidol reverses the changes in striatal glutamatergic immunolabeling following a 6-OHDA lesion.
Meshul CK; Allen C
Synapse; 2000 May; 36(2):129-42. PubMed ID: 10767060
[TBL] [Abstract][Full Text] [Related]
3. Nicotine alters striatal glutamate function and decreases the apomorphine-induced contralateral rotations in 6-OHDA-lesioned rats.
Meshul CK; Kamel D; Moore C; Kay TS; Krentz L
Exp Neurol; 2002 May; 175(1):257-74. PubMed ID: 12009777
[TBL] [Abstract][Full Text] [Related]
4. Lesion of subthalamic or motor thalamic nucleus in 6-hydroxydopamine-treated rats: effects on striatal glutamate and apomorphine-induced contralateral rotations.
Touchon JC; Moore C; Frederickson J; Meshul CK
Synapse; 2004 Mar; 51(4):287-98. PubMed ID: 14696016
[TBL] [Abstract][Full Text] [Related]
5. Alterations in rat striatal glutamate synapses following a lesion of the cortico- and/or nigrostriatal pathway.
Meshul CK; Cogen JP; Cheng HW; Moore C; Krentz L; McNeill TH
Exp Neurol; 2000 Sep; 165(1):191-206. PubMed ID: 10964498
[TBL] [Abstract][Full Text] [Related]
6. NMDA receptors mediate an early up-regulation of brain-derived neurotrophic factor expression in substantia nigra in a rat model of presymptomatic Parkinson's disease.
Bustos G; Abarca J; Bustos V; Riquelme E; Noriega V; Moya C; Campusano J
J Neurosci Res; 2009 Aug; 87(10):2308-18. PubMed ID: 19326433
[TBL] [Abstract][Full Text] [Related]
7. l-dopa-induced reversal in striatal glutamate following partial depletion of nigrostriatal dopamine with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.
Holmer HK; Keyghobadi M; Moore C; Meshul CK
Neuroscience; 2005; 136(1):333-41. PubMed ID: 16198485
[TBL] [Abstract][Full Text] [Related]
8. Haloperidol-induced morphological alterations are associated with changes in calcium/calmodulin kinase II activity and glutamate immunoreactivity.
Meshul CK; Tan SE
Synapse; 1994 Nov; 18(3):205-17. PubMed ID: 7855733
[TBL] [Abstract][Full Text] [Related]
9. Differential interaction of competitive NMDA and AMPA antagonists with selective dopamine D-1 and D-2 agonists in a rat model of Parkinson's disease.
Löschmann PA; Wüllner U; Heneka MT; Schulz JB; Kunow M; Wachtel H; Klockgether T
Synapse; 1997 Aug; 26(4):381-91. PubMed ID: 9215597
[TBL] [Abstract][Full Text] [Related]
10. Role of NMDA and AMPA glutamate receptors in the induction and the expression of dopamine-mediated sensitization in 6-hydroxydopamine-lesioned rats.
Pollack AE; St Martin JL; MacPherson AT
Synapse; 2005 Apr; 56(1):45-53. PubMed ID: 15700284
[TBL] [Abstract][Full Text] [Related]
11. Substantia nigra glutamate antagonists produce contralateral turning and basal ganglia Fos expression: interactions with D1 and D2 dopamine receptor agonists.
McPherson RJ; Marshall JF
Synapse; 2000 Jun; 36(3):194-204. PubMed ID: 10819899
[TBL] [Abstract][Full Text] [Related]
12. NMDA receptors modulate dopamine loss due to energy impairment in the substantia nigra but not striatum.
Zeevalk GD; Manzino L; Sonsalla PK
Exp Neurol; 2000 Feb; 161(2):638-46. PubMed ID: 10686083
[TBL] [Abstract][Full Text] [Related]
13. Dietary restriction affects striatal glutamate in the MPTP-induced mouse model of nigrostriatal degeneration.
Holmer HK; Keyghobadi M; Moore C; Menashe RA; Meshul CK
Synapse; 2005 Aug; 57(2):100-12. PubMed ID: 15906381
[TBL] [Abstract][Full Text] [Related]
14. Alterations in nigral NMDA and GABAA receptor control of the striatal dopamine level after repetitive exposures to nitrogen narcosis.
Lavoute C; Weiss M; Rostain JC
Exp Neurol; 2008 Jul; 212(1):63-70. PubMed ID: 18452916
[TBL] [Abstract][Full Text] [Related]
15. Differential regulation of glutamate, aspartate and gamma-amino-butyrate release by N-methyl-D-aspartate receptors in rat striatum after partial and extensive lesions to the nigro-striatal dopamine pathway.
Abarca J; Bustos G
Neurochem Int; 1999 Jul; 35(1):19-33. PubMed ID: 10403427
[TBL] [Abstract][Full Text] [Related]
16. Regulation of cholecystokinin mRNA content in rat striatum: a glutamatergic hypothesis.
Ding XZ; Mocchetti I
J Pharmacol Exp Ther; 1992 Oct; 263(1):368-73. PubMed ID: 1403798
[TBL] [Abstract][Full Text] [Related]
17. Striatal NTS1 , dopamine D2 and NMDA receptor regulation of pallidal GABA and glutamate release--a dual-probe microdialysis study in the intranigral 6-hydroxydopamine unilaterally lesioned rat.
Ferraro L; O'Connor WT; Beggiato S; Tomasini MC; Fuxe K; Tanganelli S; Antonelli T
Eur J Neurosci; 2012 Jan; 35(2):207-20. PubMed ID: 22211865
[TBL] [Abstract][Full Text] [Related]
18. Failure of MK-801 to suppress D1 receptor-mediated induction of locomotor activity and striatal preprotachykinin mRNA expression in the dopamine-depleted rat.
Campbell BM; Kreipke CW; Walker PD
Neuroscience; 2006; 137(2):505-17. PubMed ID: 16289829
[TBL] [Abstract][Full Text] [Related]
19. NMDA receptor antagonism potentiates the L-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats.
El Arfani A; Bentea E; Aourz N; Ampe B; De Deurwaerdère P; Van Eeckhaut A; Massie A; Sarre S; Smolders I; Michotte Y
Neuropharmacology; 2014 Oct; 85():198-205. PubMed ID: 24863042
[TBL] [Abstract][Full Text] [Related]
20. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Van De Witte SV; Groenewegen HJ; Voorn P
Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
